Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
OPTIMIZE
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
- NCT06001385 ↗
- Active, not recruiting
- Center for International Blood and Marrow Transplant Research
- Focused
We haven't built an HCP commentary report on OPTIMIZE (busulfan, fludarabine and 6 more in Acute Lymphoblastic Leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on OPTIMIZE so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Leukemia; Myelodysplastic Syndromes; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lymphoma; Chronic Myelomonocytic Leukemia; Pro-Lymphocytic Leukemia; Myelofibrosis
- Interventions
- Busulfan; Fludarabine; PBSC Hematopoietic Stem Cell Transplantation (HSCT); Post-Transplant Cyclophosphamide; Mesna; Tacrolimus; Mycophenolate Mofetil; Patient Reported Outcomes; Melphalan; Total-body irradiation; Cyclophosphamide
- Arms
- Regimen A (MAC: Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy · Experimental
- Regimen B (MAC: Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy · Experimental
- Regimen C (RIC: Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy · Experimental
- Regimen D (RIC: Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy · Experimental
- Regimen E (NMA: Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy · Experimental
- Enrollment
- 313 (estimated)
- Primary outcomes
- Infection Free Survival
- Sponsor
- Center for International Blood and Marrow Transplant Research with National Marrow Donor Program
- Start
- Dec 8, 2023
- Primary completion
- Dec 24, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06001385 · updated Aug 17, 2026